ID BGLR_ECOLI Reviewed; 603 AA. AC P05804; DT 01-NOV-1988, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1994, sequence version 2. DT 24-JAN-2024, entry version 182. DE RecName: Full=Beta-glucuronidase {ECO:0000303|PubMed:26364932, ECO:0000303|PubMed:3105604}; DE Short=GUS {ECO:0000303|PubMed:26364932}; DE EC=3.2.1.31 {ECO:0000269|PubMed:21051639, ECO:0000269|PubMed:23690068, ECO:0000269|PubMed:26364932, ECO:0000269|PubMed:3105604}; DE AltName: Full=Beta-D-glucuronoside glucuronosohydrolase; DE AltName: Full=EcGUS {ECO:0000303|PubMed:26364932}; DE AltName: Full=UID {ECO:0000303|PubMed:3105604}; GN Name=uidA; Synonyms=gurA, gusA; OrderedLocusNames=b1617, JW1609; OS Escherichia coli (strain K12). OC Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales; OC Enterobacteriaceae; Escherichia. OX NCBI_TaxID=83333; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-11. RX PubMed=3534890; DOI=10.1073/pnas.83.22.8447; RA Jefferson R.A., Burgess S.M., Hirsh D.; RT "Beta-glucuronidase from Escherichia coli as a gene-fusion marker."; RL Proc. Natl. Acad. Sci. U.S.A. 83:8447-8451(1986). RN [2] RP SEQUENCE REVISION TO 279. RX PubMed=8125312; DOI=10.1016/0378-1119(94)90820-6; RA Schlaman H.R., Risseeuw E., Franke-Van Dijk M.E., Hooykaas P.J.; RT "Nucleotide sequence corrections of the uidA open reading frame encoding RT beta-glucuronidase."; RL Gene 138:259-260(1994). RN [3] RP SEQUENCE REVISION TO 420-425. RX PubMed=2103475; DOI=10.1007/bf00039422; RA Farrell L.B., Beachy R.N.; RT "Manipulation of beta-glucuronidase for use as a reporter in vacuolar RT targeting studies."; RL Plant Mol. Biol. 15:821-825(1990). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911; RX PubMed=9097039; DOI=10.1093/dnares/3.6.363; RA Aiba H., Baba T., Fujita K., Hayashi K., Inada T., Isono K., Itoh T., RA Kasai H., Kashimoto K., Kimura S., Kitakawa M., Kitagawa M., Makino K., RA Miki T., Mizobuchi K., Mori H., Mori T., Motomura K., Nakade S., RA Nakamura Y., Nashimoto H., Nishio Y., Oshima T., Saito N., Sampei G., RA Seki Y., Sivasundaram S., Tagami H., Takeda J., Takemoto K., Takeuchi Y., RA Wada C., Yamamoto Y., Horiuchi T.; RT "A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to RT the 28.0-40.1 min region on the linkage map."; RL DNA Res. 3:363-377(1996). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=K12 / MG1655 / ATCC 47076; RX PubMed=9278503; DOI=10.1126/science.277.5331.1453; RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V., RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F., RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B., RA Shao Y.; RT "The complete genome sequence of Escherichia coli K-12."; RL Science 277:1453-1462(1997). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911; RX PubMed=16738553; DOI=10.1038/msb4100049; RA Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S., RA Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.; RT "Highly accurate genome sequences of Escherichia coli K-12 strains MG1655 RT and W3110."; RL Mol. Syst. Biol. 2:E1-E5(2006). RN [7] RP PROTEIN SEQUENCE OF 1-5, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY. RX PubMed=3105604; DOI=10.1016/0300-9084(87)90248-3; RA Blanco C., Nemoz G.; RT "One step purification of Escherichia coli beta-glucuronidase."; RL Biochimie 69:157-161(1987). RN [8] RP CHARACTERIZATION. RA Jefferson R.A.; RL Thesis (1985), University of Colorado, United States. RN [9] {ECO:0007744|PDB:3K46, ECO:0007744|PDB:3K4A, ECO:0007744|PDB:3K4D, ECO:0007744|PDB:3LPF, ECO:0007744|PDB:3LPG} RP X-RAY CRYSTALLOGRAPHY (2.26 ANGSTROMS) OF APOENZYME AND COMPLEXES WITH RP GLUCARO-D-LACTAM INHIBITOR AND OTHER INHIBITORS, FUNCTION, CATALYTIC RP ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21051639; DOI=10.1126/science.1191175; RA Wallace B.D., Wang H., Lane K.T., Scott J.E., Orans J., Koo J.S., RA Venkatesh M., Jobin C., Yeh L.A., Mani S., Redinbo M.R.; RT "Alleviating cancer drug toxicity by inhibiting a bacterial enzyme."; RL Science 330:831-835(2010). RN [10] {ECO:0007744|PDB:4JHZ} RP X-RAY CRYSTALLOGRAPHY (2.83 ANGSTROMS) OF 1-601 IN COMPLEX WITH AN RP INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=23690068; DOI=10.1124/mol.113.085852; RA Roberts A.B., Wallace B.D., Venkatesh M.K., Mani S., Redinbo M.R.; RT "Molecular insights into microbial beta-glucuronidase inhibition to RT abrogate CPT-11 toxicity."; RL Mol. Pharmacol. 84:208-217(2013). RN [11] {ECO:0007744|PDB:5CZK} RP X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS) IN COMPLEX WITH INHIBITOR R1, N-K RP MOTIF, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND RP ACTIVITY REGULATION. RX PubMed=26364932; DOI=10.1016/j.chembiol.2015.08.005; RA Wallace B.D., Roberts A.B., Pollet R.M., Ingle J.D., Biernat K.A., RA Pellock S.J., Venkatesh M.K., Guthrie L., O'Neal S.K., Robinson S.J., RA Dollinger M., Figueroa E., McShane S.R., Cohen R.D., Jin J., Frye S.V., RA Zamboni W.C., Pepe-Ranney C., Mani S., Kelly L., Redinbo M.R.; RT "Structure and Inhibition of Microbiome beta-Glucuronidases Essential to RT the Alleviation of Cancer Drug Toxicity."; RL Chem. Biol. 22:1238-1249(2015). RN [12] {ECO:0007744|PDB:6LEG, ECO:0007744|PDB:6LEJ, ECO:0007744|PDB:6LEL, ECO:0007744|PDB:6LEM} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) IN COMPLEXES WITH INHIBITORS, RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=33664385; DOI=10.1038/s42003-021-01815-w; RA Lin H.Y., Chen C.Y., Lin T.C., Yeh L.F., Hsieh W.C., Gao S., Burnouf P.A., RA Chen B.M., Hsieh T.J., Dashnyam P., Kuo Y.H., Tu Z., Roffler S.R., RA Lin C.H.; RT "Entropy-driven binding of gut bacterial beta-glucuronidase inhibitors RT ameliorates irinotecan-induced toxicity."; RL Commun. Biol. 4:280-280(2021). RN [13] {ECO:0007744|PDB:7PR6} RP X-RAY CRYSTALLOGRAPHY (1.99 ANGSTROMS) IN COVALENT COMPLEX WITH AN RP INHIBITOR, AND ACTIVE SITE. RX PubMed=35881786; DOI=10.1073/pnas.2203167119; RA de Boer C., Armstrong Z., Lit V.A.J., Barash U., Ruijgrok G., Boyango I., RA Weitzenberg M.M., Schroeder S.P., Sarris A.J.C., Meeuwenoord N.J., Bule P., RA Kayal Y., Ilan N., Codee J.D.C., Vlodavsky I., Overkleeft H.S., RA Davies G.J., Wu L.; RT "Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2203167119-e2203167119(2022). CC -!- FUNCTION: Displays beta-glucuronidase activity with the artificial CC substrate p-nitrophenyl-beta-D-glucuronide (PNPG) and with 4- CC methylumbelliferyl-glucuronide (PubMed:26364932, PubMed:3105604, CC PubMed:21051639, PubMed:23690068, PubMed:33664385). Is likely capable CC of scavenging glucuronate from a range of chemically distinct CC xenobiotic and endobiotic glucuronides present in the gastrointestinal CC (GI) tract, to be able to utilize these diverse sources of carbon. As CC part of the GI microbiome, this enzyme is able to reactivate CC glucuronide drug conjugates, such reactivated compounds can CC significantly damage the GI tract (PubMed:26364932). CC {ECO:0000269|PubMed:21051639, ECO:0000269|PubMed:23690068, CC ECO:0000269|PubMed:26364932, ECO:0000269|PubMed:3105604, CC ECO:0000269|PubMed:33664385}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-glucuronoside + H2O = an alcohol + D-glucuronate; CC Xref=Rhea:RHEA:17633, ChEBI:CHEBI:15377, ChEBI:CHEBI:30879, CC ChEBI:CHEBI:58720, ChEBI:CHEBI:83411; EC=3.2.1.31; CC Evidence={ECO:0000269|PubMed:21051639, ECO:0000269|PubMed:23690068, CC ECO:0000269|PubMed:26364932, ECO:0000269|PubMed:3105604, CC ECO:0000269|PubMed:33664385}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17634; CC Evidence={ECO:0000305|PubMed:26364932}; CC -!- CATALYTIC ACTIVITY: CC Reaction=4-methylumbelliferone beta-D-glucuronate + H2O = 4- CC methylumbelliferone + D-glucuronate; Xref=Rhea:RHEA:76111, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:17224, ChEBI:CHEBI:58720, CC ChEBI:CHEBI:144582; Evidence={ECO:0000269|PubMed:21051639, CC ECO:0000269|PubMed:33664385}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:76112; CC Evidence={ECO:0000305|PubMed:21051639}; CC -!- ACTIVITY REGULATION: Potently inhibited by a set of synthetic compounds CC like thio-urea derivatives and analogs, and uronic isofagomine (UIFG) CC derivatives. Inhibitors of gut microbial beta-glucuronidases block the CC reactivation of glucuronidated cancer drugs, and thereby alleviate CC drug-induced GI toxicity. {ECO:0000269|PubMed:21051639, CC ECO:0000269|PubMed:23690068, ECO:0000269|PubMed:26364932, CC ECO:0000269|PubMed:33664385}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.13 mM for p-nitrophenyl-beta-D-glucuronide CC {ECO:0000269|PubMed:26364932}; CC Note=kcat is 120 sec(-1) with p-nitrophenyl-beta-D-glucuronide as CC substrate. {ECO:0000269|PubMed:26364932}; CC pH dependence: CC Optimum pH is 5.0-7.5.; CC Temperature dependence: CC Resistant to thermal inactivation at 50 degrees Celsius.; CC -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:21051639, CC ECO:0000269|PubMed:3105604}. CC -!- DOMAIN: The N-K motif seems to be a discriminant that could be employed CC as a fingerprint to identify beta-glucuronidases from the large GH2 CC family of proteins. {ECO:0000305|PubMed:26364932}. CC -!- SIMILARITY: Belongs to the glycosyl hydrolase 2 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M14641; AAA68923.1; ALT_SEQ; Genomic_DNA. DR EMBL; S69414; AAB30197.1; -; Genomic_DNA. DR EMBL; U00096; AAC74689.1; -; Genomic_DNA. DR EMBL; AP009048; BAA15368.1; -; Genomic_DNA. DR PIR; C64918; GBECGC. DR RefSeq; NP_416134.1; NC_000913.3. DR RefSeq; WP_000945878.1; NZ_SSZK01000001.1. DR PDB; 3K46; X-ray; 2.50 A; A/B=1-603. DR PDB; 3K4A; X-ray; 2.90 A; A/B=1-603. DR PDB; 3K4D; X-ray; 2.39 A; A/B=1-603. DR PDB; 3LPF; X-ray; 2.26 A; A/B=1-603. DR PDB; 3LPG; X-ray; 2.42 A; A/B=1-603. DR PDB; 4JHZ; X-ray; 2.83 A; A/B=1-601. DR PDB; 5CZK; X-ray; 2.39 A; A/B=1-603. DR PDB; 6LEG; X-ray; 2.60 A; A/B/C/D=1-603. DR PDB; 6LEJ; X-ray; 2.62 A; A/B=1-603. DR PDB; 6LEL; X-ray; 2.50 A; A/B=1-603. DR PDB; 6LEM; X-ray; 3.19 A; A/B=1-603. DR PDB; 7PR6; X-ray; 1.99 A; AAA/BBB=18-599. DR PDBsum; 3K46; -. DR PDBsum; 3K4A; -. DR PDBsum; 3K4D; -. DR PDBsum; 3LPF; -. DR PDBsum; 3LPG; -. DR PDBsum; 4JHZ; -. DR PDBsum; 5CZK; -. DR PDBsum; 6LEG; -. DR PDBsum; 6LEJ; -. DR PDBsum; 6LEL; -. DR PDBsum; 6LEM; -. DR PDBsum; 7PR6; -. DR AlphaFoldDB; P05804; -. DR SMR; P05804; -. DR BioGRID; 4263483; 12. DR DIP; DIP-11086N; -. DR IntAct; P05804; 2. DR STRING; 511145.b1617; -. DR BindingDB; P05804; -. DR ChEMBL; CHEMBL3217380; -. DR CAZy; GH2; Glycoside Hydrolase Family 2. DR jPOST; P05804; -. DR PaxDb; 511145-b1617; -. DR EnsemblBacteria; AAC74689; AAC74689; b1617. DR GeneID; 75204461; -. DR GeneID; 946149; -. DR KEGG; ecj:JW1609; -. DR KEGG; eco:b1617; -. DR PATRIC; fig|1411691.4.peg.644; -. DR EchoBASE; EB1048; -. DR eggNOG; COG3250; Bacteria. DR HOGENOM; CLU_006501_6_1_6; -. DR InParanoid; P05804; -. DR OMA; IHDHVGW; -. DR OrthoDB; 9758603at2; -. DR PhylomeDB; P05804; -. DR BioCyc; EcoCyc:BETA-GLUCURONID-MONOMER; -. DR BioCyc; MetaCyc:BETA-GLUCURONID-MONOMER; -. DR BRENDA; 3.2.1.31; 2026. DR SABIO-RK; P05804; -. DR EvolutionaryTrace; P05804; -. DR PRO; PR:P05804; -. DR Proteomes; UP000000318; Chromosome. DR Proteomes; UP000000625; Chromosome. DR GO; GO:0005829; C:cytosol; IDA:EcoCyc. DR GO; GO:0032991; C:protein-containing complex; IDA:EcoCyc. DR GO; GO:0004566; F:beta-glucuronidase activity; IDA:EcoCyc. DR GO; GO:0030246; F:carbohydrate binding; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IDA:EcoCyc. DR GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro. DR GO; GO:0019391; P:glucuronoside catabolic process; IMP:EcoCyc. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 3.20.20.80; Glycosidases; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR InterPro; IPR036156; Beta-gal/glucu_dom_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR006101; Glyco_hydro_2. DR InterPro; IPR023232; Glyco_hydro_2_AS. DR InterPro; IPR006103; Glyco_hydro_2_cat. DR InterPro; IPR023230; Glyco_hydro_2_CS. DR InterPro; IPR006102; Glyco_hydro_2_Ig-like. DR InterPro; IPR006104; Glyco_hydro_2_N. DR InterPro; IPR017853; Glycoside_hydrolase_SF. DR InterPro; IPR013783; Ig-like_fold. DR PANTHER; PTHR10066; BETA-GLUCURONIDASE; 1. DR PANTHER; PTHR10066:SF67; BETA-GLUCURONIDASE; 1. DR Pfam; PF00703; Glyco_hydro_2; 1. DR Pfam; PF02836; Glyco_hydro_2_C; 1. DR Pfam; PF02837; Glyco_hydro_2_N; 1. DR PRINTS; PR00132; GLHYDRLASE2. DR SUPFAM; SSF51445; (Trans)glycosidases; 1. DR SUPFAM; SSF49303; beta-Galactosidase/glucuronidase domain; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR PROSITE; PS00719; GLYCOSYL_HYDROL_F2_1; 1. DR PROSITE; PS00608; GLYCOSYL_HYDROL_F2_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Direct protein sequencing; Glycosidase; Hydrolase; KW Reference proteome. FT CHAIN 1..603 FT /note="Beta-glucuronidase" FT /id="PRO_0000057680" FT MOTIF 566..568 FT /note="N-K motif" FT /evidence="ECO:0000305|PubMed:26364932" FT ACT_SITE 413 FT /note="Proton donor" FT /evidence="ECO:0000305|PubMed:21051639" FT ACT_SITE 504 FT /note="Nucleophile" FT /evidence="ECO:0000269|PubMed:35881786, FT ECO:0000305|PubMed:21051639" FT BINDING 163 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 412 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 466 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 472 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 504 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 549 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT BINDING 568 FT /ligand="D-glucuronate" FT /ligand_id="ChEBI:CHEBI:58720" FT /evidence="ECO:0000305|PubMed:21051639, FT ECO:0007744|PDB:3K4D" FT STRAND 6..8 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 18..26 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 29..33 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 34..36 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 43..49 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 52..55 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 58..61 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 65..74 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 77..79 FT /evidence="ECO:0007829|PDB:5CZK" FT STRAND 80..82 FT /evidence="ECO:0007829|PDB:3K46" FT STRAND 83..89 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 92..101 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 114..117 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 126..135 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 146..150 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 152..154 FT /evidence="ECO:0007829|PDB:6LEM" FT STRAND 156..164 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 174..179 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 181..191 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 194..197 FT /evidence="ECO:0007829|PDB:3LPG" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 211..217 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 219..221 FT /evidence="ECO:0007829|PDB:3K46" FT STRAND 223..228 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:6LEM" FT STRAND 233..235 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 244..246 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 250..257 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 262..269 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 290..295 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 300..304 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 308..321 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 335..344 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 347..351 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 359..361 FT /evidence="ECO:0007829|PDB:6LEL" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:3LPG" FT STRAND 374..376 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 377..379 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 382..399 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 405..413 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 421..435 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 447..449 FT /evidence="ECO:0007829|PDB:3K46" FT TURN 451..453 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 457..459 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 460..466 FT /evidence="ECO:0007829|PDB:3LPF" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 472..474 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 478..496 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 500..504 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:3K4D" FT HELIX 523..537 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 543..552 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 558..561 FT /evidence="ECO:0007829|PDB:3K4A" FT STRAND 562..566 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 569..571 FT /evidence="ECO:0007829|PDB:3LPF" FT HELIX 580..590 FT /evidence="ECO:0007829|PDB:3LPF" FT STRAND 598..600 FT /evidence="ECO:0007829|PDB:3K4A" SQ SEQUENCE 603 AA; 68447 MW; E769C8D61A3B9A76 CRC64; MLRPVETPTR EIKKLDGLWA FSLDRENCGI DQRWWESALQ ESRAIAVPGS FNDQFADADI RNYAGNVWYQ REVFIPKGWA GQRIVLRFDA VTHYGKVWVN NQEVMEHQGG YTPFEADVTP YVIAGKSVRI TVCVNNELNW QTIPPGMVIT DENGKKKQSY FHDFFNYAGI HRSVMLYTTP NTWVDDITVV THVAQDCNHA SVDWQVVANG DVSVELRDAD QQVVATGQGT SGTLQVVNPH LWQPGEGYLY ELCVTAKSQT ECDIYPLRVG IRSVAVKGEQ FLINHKPFYF TGFGRHEDAD LRGKGFDNVL MVHDHALMDW IGANSYRTSH YPYAEEMLDW ADEHGIVVID ETAAVGFNLS LGIGFEAGNK PKELYSEEAV NGETQQAHLQ AIKELIARDK NHPSVVMWSI ANEPDTRPQG AREYFAPLAE ATRKLDPTRP ITCVNVMFCD AHTDTISDLF DVLCLNRYYG WYVQSGDLET AEKVLEKELL AWQEKLHQPI IITEYGVDTL AGLHSMYTDM WSEEYQCAWL DMYHRVFDRV SAVVGEQVWN FADFATSQGI LRVGGNKKGI FTRDRKPKSA AFLLQKRWTG MNFGEKPQQG GKQ //